AG
ARRY

Algert Global’s Array Biopharma Inc ARRY Stock Holding History

Algert Global’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,802
Closed -$113K – 397
2016
Q4 		$113K Hold
12,802
– – 0.03% 315
2016
Q3 		$86K Buy
+12,802
New +$49.5K 0.02% 356
2015
Q3 		– Sell
-19,770
Closed -$143K – 367
2015
Q2 		$143K Buy
+19,770
New +$146K 0.08% 295

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Algert Global's ARRY Position: Q1 2017 in Review

Algert Global sold out of Array Biopharma Inc (ARRY) in Q1 2017, closing a stake of 12,802 shares — an estimated $113K sold.

Algert Global first reported a position in ARRY in Q2 2015 and held it in 3 quarters. The position peaked at $143K in Q2 2015. 187 funds tracked by Wall St. Rank hold ARRY as of Q1 2017.

  • Algert Global reported no remaining Array Biopharma Inc position as of Q1 2017 after selling out during the quarter.
  • Algert Global sold 12,802 Array Biopharma Inc shares in Q1 2017, an estimated $113K.
  • Algert Global first reported a position in Array Biopharma Inc in Q2 2015 and held it in 3 quarters.
  • Algert Global's Array Biopharma Inc position peaked at $143K in Q2 2015.
  • 187 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2017.

Based on Algert Global's 13F filing for Q1 2017, filed 2 May 2017.